Inflammation and cardiovascular drugs - Revision history

Abhay.goel.1: /* Cardiovascular diseases */

2012-04-20T15:29:55Z

‎Cardiovascular diseases

Abhay.goel.1: /* Overview of inflammation */

2012-04-20T15:17:44Z

‎Overview of inflammation

Abhay.goel.1: /* Targeting inflammation – Pharmaceutical focus */

2012-04-20T15:16:09Z

‎Targeting inflammation – Pharmaceutical focus

Abhay.goel.1: /* Targeting inflammation – Pharmaceutical focus */

2012-04-20T15:15:03Z

‎Targeting inflammation – Pharmaceutical focus

Abhay.goel.1: /* Targeting inflammation – Pharmaceutical focus */

2012-04-20T15:14:49Z

‎Targeting inflammation – Pharmaceutical focus

Manikandan: /* Like this report? */

2009-08-06T06:24:31Z

‎<span style="color:#C41E3A">Like this report?</span>

Manikandan: /* Like this report? */

2009-08-06T06:23:52Z

‎<span style="color:#C41E3A">Like this report?</span>

Manikandan: /* Future potential areas */

2009-08-06T06:23:03Z

‎Future potential areas

Manikandan: /* C-reactive protein (CRP) */

2009-08-06T06:22:35Z

‎C-reactive protein (CRP)

Manikandan: /* Contact Dolcera */

2009-04-30T08:15:26Z

‎Contact Dolcera

@@ Line 193: / Line 193: @@
 * Several angiogenic and myogenic stem cell therapies are under investigation and promise in the long run to advance cardiac rehabilitation and even prevent heart failure. Despite the development of improved therapies, millions of Americans continue to live with life-threatening cardiovascular diseases.
-[[image:cardiovascilar diseases.png|center|thumb|800 px| [http://www-ermm.cbcu.cam.ac.uk/0500918Xh.htm Source]]]
+[[image:cardiovascilar diseases.png|center|thumb|2000px| [http://www-ermm.cbcu.cam.ac.uk/0500918Xh.htm Source]]]
 ----
@@ Line 326: / Line 326: @@
 ----
 ==Drug targets==

@@ Line 15: / Line 15: @@
 Inflammation is characterized by:
-* increased blood flow to the tissue causing
+* increased blood flow to the tissue
 * increased temperature,
 * redness,

@@ Line 5: / Line 5: @@
 Inflammation is one of the key processes linked to various diseases and disorders. There are many opportunities for designing and developing specific new drugs for inflammatory responses.
-[[image:market.png|center|800 px|thumb|[http://www.chromos.com/documents/roadshowsept14_003.pdf Source]]]
+[[image:market.png|center|1200 px|thumb|[http://www.chromos.com/documents/roadshowsept14_003.pdf Source]]]
 ----

@@ Line 5: / Line 5: @@
 Inflammation is one of the key processes linked to various diseases and disorders. There are many opportunities for designing and developing specific new drugs for inflammatory responses.
-[[image:market.png|center|500 px|thumb|[http://www.chromos.com/documents/roadshowsept14_003.pdf Source]]]
+[[image:market.png|center|800 px|thumb|[http://www.chromos.com/documents/roadshowsept14_003.pdf Source]]]
 ----

@@ Line 5: / Line 5: @@
 Inflammation is one of the key processes linked to various diseases and disorders. There are many opportunities for designing and developing specific new drugs for inflammatory responses.
-[[image:market.png|center|350 px|thumb|[http://www.chromos.com/documents/roadshowsept14_003.pdf Source]]]
+[[image:market.png|center|500 px|thumb|[http://www.chromos.com/documents/roadshowsept14_003.pdf Source]]]
 ----

@@ Line 411: / Line 411: @@
 '''Dolcera can provide a comprehensive report customized to your needs'''</p>
 {|border="2" cellspacing="0" cellpadding="4" align="center" "
-|style="background:lightgrey" align = "center"  colspan = "3"|'''[mailto:info@dolcera.com <span style="color:#0047AB">Buy the customized Alopecia report from Dolcera</span>]'''
+|style="background:lightgrey" align = "center"  colspan = "3"|'''[mailto:info@dolcera.com <span style="color:#0047AB">Buy the customized report from Dolcera</span>]'''
 |-
 | align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services Patent Analytics Services]

← Older revision		Revision as of 06:23, 6 August 2009
Line 544:		Line 544:
	# In vivo activation of '''G{alpha}q/PKC pathways'' could upregulate GRK2 expression in cardiovascular cells, thus contributing to the increased desensitization of ß-adrenergic and other GPCR systems, is of potential physiological relevance. Detailed mechanisms of regulation of GRK2 expression in different types of cells of the cardiovascular system, particularly in cardiac cell lines, and the determination of possible changes in GRK2 levels in VSMCs of patients with cardiovascular diseases are interesting fields for future research and may help to develop new therapeutic strategies based on the modulation of GRK2 expression. [http://circ.ahajournals.org/cgi/content/full/circulationaha;101/17/2083]]		# In vivo activation of '''G{alpha}q/PKC pathways'' could upregulate GRK2 expression in cardiovascular cells, thus contributing to the increased desensitization of ß-adrenergic and other GPCR systems, is of potential physiological relevance. Detailed mechanisms of regulation of GRK2 expression in different types of cells of the cardiovascular system, particularly in cardiac cell lines, and the determination of possible changes in GRK2 levels in VSMCs of patients with cardiovascular diseases are interesting fields for future research and may help to develop new therapeutic strategies based on the modulation of GRK2 expression. [http://circ.ahajournals.org/cgi/content/full/circulationaha;101/17/2083]]

		+	==<span style="color:#C41E3A">Like this report?</span>==
		+	<p align="center"> '''This is only a sample report with brief analysis''' <br>
		+	'''Dolcera can provide a comprehensive report customized to your needs'''</p>
		+	{\|border="2" cellspacing="0" cellpadding="4" align="center" "
		+	\|style="background:lightgrey" align = "center" colspan = "3"\|'''[mailto:info@dolcera.com <span style="color:#0047AB">Buy the customized Alopecia report from Dolcera</span>]'''
		+	\|-
		+	\| align = "center"\| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services Patent Analytics Services]
		+	\|align = "center"\| [http://www.dolcera.com/website_prod/services/business-research-services Market Research Services]
		+	\|align = "center"\| [http://www.dolcera.com/website_prod/tools/patent-dashboard Purchase Patent Dashboard]
		+	\|-
		+	\|align = "center"\| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Landscape Services]
		+	\|align = "center"\| [http://www.dolcera.com/website_prod/research-processes Dolcera Processes]
		+	\|align = "center"\| [http://www.dolcera.com/website_prod/industries Industry Focus]
		+	\|-
		+	\|align = "center"\| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Search Services]
		+	\|align = "center"\| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/alerts-and-updates Patent Alerting Services]
		+	\|align = "center"\| [http://www.dolcera.com/website_prod/tools Dolcera Tools]
		+	\|-
		+	\|}
		+	<br>

	==Contact Dolcera==		==Contact Dolcera==

← Older revision		Revision as of 06:22, 6 August 2009
Line 406:		Line 406:

	----		----
		+
		+	==<span style="color:#C41E3A">Like this report?</span>==
		+	<p align="center"> '''This is only a sample report with brief analysis''' <br>
		+	'''Dolcera can provide a comprehensive report customized to your needs'''</p>
		+	{\|border="2" cellspacing="0" cellpadding="4" align="center" "
		+	\|style="background:lightgrey" align = "center" colspan = "3"\|'''[mailto:info@dolcera.com <span style="color:#0047AB">Buy the customized Alopecia report from Dolcera</span>]'''
		+	\|-
		+	\| align = "center"\| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services Patent Analytics Services]
		+	\|align = "center"\| [http://www.dolcera.com/website_prod/services/business-research-services Market Research Services]
		+	\|align = "center"\| [http://www.dolcera.com/website_prod/tools/patent-dashboard Purchase Patent Dashboard]
		+	\|-
		+	\|align = "center"\| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Landscape Services]
		+	\|align = "center"\| [http://www.dolcera.com/website_prod/research-processes Dolcera Processes]
		+	\|align = "center"\| [http://www.dolcera.com/website_prod/industries Industry Focus]
		+	\|-
		+	\|align = "center"\| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Search Services]
		+	\|align = "center"\| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/alerts-and-updates Patent Alerting Services]
		+	\|align = "center"\| [http://www.dolcera.com/website_prod/tools Dolcera Tools]
		+	\|-
		+	\|}
		+	<br>

	===C-reactive protein (CRP)===		===C-reactive protein (CRP)===

@@ Line 526: / Line 526: @@
 ==Contact Dolcera==
-'''Samir Raiyani'''
+{| style="border:1px solid #AAA; background:#E9E9E9" align="center"
+|-
-'''201 A South Delaware St. #306'''
+! style="background:lightgrey" | Samir Raiyani
-'''San Mateo, CA 94401 USA'''
+|-
-'''Phone: +1-650-269-7952'''
+| '''Email''': [mailto:info@dolcera.com info@dolcera.com]
-'''Fax: +1-866-690-7517'''
+|-
-'''info@dolcera.com'''
+| '''Phone''': +1-650-269-7952